Lilly’s once‑daily pill posts late‑stage successes. Here’s what the data really say, how it stacks up against rivals, and what to expect on price, coverage, and patient experience.

Novo Nordisk faced critical leadership changes and mounting challenges from Pharmacy Benefit Managers (PBMs) amid fierce competition in the obesity drug market. With a new CEO recently appointed, the company is also doubling down on strategic partnerships in China, aiming to innovate its research pipeline. However, questions remain about the global acceptance of clinical data from these collaborations and the sustainability of Novo’s market position.

The “Research Use Only” Peptide Market Isn’t Slowing Down—It’s Evolving

Novo Nordisk ousted its longtime CEO just two weeks after scoring a major win with CVS Caremark, which named Wegovy its preferred weight-loss drug and dropped Eli Lilly’s Zepbound. But Lilly isn’t flinching. CEO David Ricks dismissed the move as “last decade,” signaling a shift away from exclusive PBM deals and toward direct-to-consumer access. As manufacturers double down on digital pharmacies and price cuts, the real fight for the obesity market may be happening outside the

Why do weight-loss drugs have names like Orforglipron? This article breaks down the logic behind drug naming, from science to branding—no jargon, just clarity.

Experimental weight loss drugs are being sold online for "research use only"—but many are injecting them at home.

FDA Cracks Down on Compounded Semaglutide, Eli Lilly Slashes Zepbound Prices, and Insurance Struggles Continue

Explore Medicare's groundbreaking decision to negotiate Ozempic pricing in PoundsPunch Periodical 2025.01.

Weight-Loss Drug Wars Heat Up, PBM Reform Stalls, and Insurers Push Back

Biden’s Weight-Loss Drug Proposal Faces Trump-Era Challenges, Ireland’s Crackdown on Counterfeits, and China’s Next-Gen GLP-1 Innovations

Medicare’s Lower Drug Premiums, Lilly’s Shortage Supply Resolved While Compounding Pharmacies Still in Play

Insurers Raise Premiums or Drop Coverage Due to High Costs of Weight Loss Drugs; FDA Approves New Oral Weight Loss Pill Welcome to...

Commercial Insurance Dominated Weight Loss Prescriptions, Medicare May Target Wegovy for Price Cuts, FDA Reported Eased Drug Shortages

House Bill to Expand Medicare Weight Loss Drug Coverage, The Novo Nordisk CEO to Testify in Senate, Lilly’s Approval in China and More

Weight Loss Drug & Erectile Dysfunction, Eli Lilly’s New Factory, Weight Regain after Stop Using the Drug

Wegovy and Other Drugs Now More Accessible Under Revised Medicare Rules

The new drugs, the China and India's ambition, and Bernie Sanders' pricing probe.